Robertson, Stephanie http://orcid.org/0000-0002-9843-3028
Acs, Balazs
Lippert, Michael
Hartman, Johan
Funding for this research was provided by:
Cancerfonden
MedTechLabs
Region Stockholm
Cancerföreningen i Stockholm
Swedish Breast Cancer Association
Svenska Sällskapet för Medicinsk Forskning
Article History
Received: 11 April 2020
Accepted: 13 June 2020
First Online: 22 June 2020
Compliance with ethical standards
:
: JH was former member of the advisory board at Visiopharm A/S. JH has obtained speaker’s honoraria or advisory board remunerations from Roche, Novartis, AstraZeneca, Eli Lilly and MSD. JH is co-founder and shareholder of Stratipath AB. JH has received institutional research grants from Cepheid and Novartis. ML is employee of Visiopharm A/S. SR and BA declare no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (Regional Ethical Review Board at Karolinska Institutet, Stockholm, Sweden) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Regional Ethical Review Board in Stockholm, Sweden on November 13, 2013 (No. 2013/1833-31/2).
: The study was based on retrospective clinical data, and no additional patient consent was required in accordance to ethical approval. However, prior to surgery, all patients have approved storage of material in the Stockholm medical Biobank for clinical research purposes.